Exclusive Summary

• Backed by US-FDA cGMP certification and US registration, serving as a powerful Reference Country credential to enable fast-track regulatory approval and distribution in emerging global markets like LATAM, MENA, and SEA.
• Listed on the WHO Essential Medicines List with massive baseline demand, targeting over 262 million asthma patients and 18 million rheumatoid arthritis patients globally as a fundamental first-line therapy.
• Combines China's highly efficient manufacturing cost advantages with FDA-tier quality control, providing overseas distributors with a highly profitable, reliable, and affordable commercialization asset.